---
title: "PepGen Inc. (PEPG.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/PEPG.US.md"
symbol: "PEPG.US"
name: "PepGen Inc."
industry: "Biotechnology"
---

# PepGen Inc. (PEPG.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | US Market |
| Website | [epgen.com](https://epgen.com) |

## Company Profile

PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. Its lead product candidates comprise PGN-EDO51, an EDO peptide which is Phase 2 clinical trial to treat duchenne muscular...

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -4.73 | 373/605 | - | - | - |
| PB | 2.71 | 218/605 | 2.51 | 0.61 | 0.46 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2025-12-23T05:00:00.000Z

Total Analysts: **6**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 5 | 83% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 1 | 17% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 6.44 |
| Highest Target | 20.00 |
| Lowest Target | 3.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/PEPG.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/PEPG.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/PEPG.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.